Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
To better understand your feelings and expectations about immunotherapy
Checked against the public recordLast updated Aug 6, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Behavioral: Questionnaires; Behavioral: Interview
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Patients being considered for or within 2 months of starting immunotherapy for advanced cancer 2. Patient ≥18 years of age 3. ECOG ≥2 4. Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment 5. English speaking 6. Willing to participate in the study and sign informed consent 7. The study will include medical oncologists that treat advanced cancers Exclusion Criteria: 1. Treatment for curative intent 2. Presence of Delirium (as determined by score \>13 on MDAS 46, appendix A)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- M D Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 6, 2024. Always confirm current availability with the study team.